Cellectis SA (CLLS) has released an update.
Cellectis, a clinical-stage biotechnology firm, announced the publication of a study in Scientific Reports detailing how three factors—spacer length, TALEB architecture, and base composition—significantly influence the efficiency of TALE base editors, a gene-editing tool that could advance therapeutic strategies for genetic diseases. Their research emphasizes the importance of targeted cytosine positioning for effective DNA editing, potentially enhancing the application of TALE base editors in therapeutic contexts. The company is known for developing cell and gene therapies using its TALEN gene-editing technology and PulseAgile electroporation system.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
